NEW YORK (GenomeWeb News) – UK biopharmaceutical firm Xention said today it has extended its drug discovery agreement with Japanese firm Ono Pharmaceutical for an additional year.
The companies originally signed their two-year agreement in March 2009 and have been successful in identifying multiple compounds, which selectively modulate the function of target ion channels, Xention said.